title: Bullous pemphigoid induced by PUVA therapy.
abstract: An 80-year-old psoriatic patient developed a blistering eruption during oral PUVA therapy. The diagnosis of bullous pemphigoid (BP) was established by routine histopathology, which demonstrated subepidermal blistering, and direct immunofluorescence, which revealed linear deposits of IgG, IgM and C3 along the basement membrane zone. Indirect immunofluorescence using normal human split skin revealed binding of IgG antibodies to the epidermal side, thus confirming a subepidermal blistering disorder. These proteins were identified by the immunoblotting technique as BP antigens I and II. Clinically, the lesions could be reproduced by phototesting using topical 8-methoxypsoralen. Again, the histopathological and immunopathological findings were consistent with the diagnosis of PUVA-induced BP. To the best of our knowledge, this is the first report demonstrating psoriasis-associated BP, in which the clinical diagnosis of BP is confirmed by immunoblotting analysis. The exact role of UV light in precipitating bullous lesions, particularly the question whether UV light may represent an unspecific epidermal injury leading to further attraction of autoantibodies to the basement membrane zone, as suggested recently by an experimental study in rodents, remains to be clarified in future studies.
authors.affiliation: Division of Special and Environmental Dermatology, University of Vienna, Austria.
authors.forename: S
authors.initials: S
authors.lastname: Perl
authors.forename: K
authors.initials: K
authors.lastname: Rappersberger
authors.forename: D
authors.initials: D
authors.lastname: Födinger
authors.forename: B
authors.initials: B
authors.lastname: Anegg
authors.forename: H
authors.initials: H
authors.lastname: Hönigsmann
authors.forename: B
authors.initials: B
authors.lastname: Ortel
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000032:analysis; D001485:Basement Membrane / Q000473:pathology; D003176:Complement C3 / Q000032:analysis; D004817:Epidermis / Q000473:pathology; D019085:Fluorescent Antibody Technique, Direct; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D015151:Immunoblotting; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D008297:Male; D008730:Methoxsalen / Q000009:adverse effects; D011701:PUVA Therapy / Q000009:adverse effects*; D010391:Pemphigoid, Bullous / Q000139:chemically induced* / Q000473:pathology; D017319:Photosensitizing Agents / Q000009:adverse effects; D011565:Psoriasis / Q000188:drug therapy; D012867:Skin / Q000473:pathology; D014466:Ultraviolet Rays / Q000009:adverse effects
chemical_list: D001323:Autoantibodies; D003176:Complement C3; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D017319:Photosensitizing Agents; D008730:Methoxsalen